References
- McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;334:1–6.
- Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst. 2000;92:699–708.
- Kvinnsland S. The leucocyte nadir, a predictor of chemotherapy efficacy? Br J Cancer. 1999;80:1681.
- Rocconi RP, Matthews KS, Kemper MK, Hoskins KE, Barnes MN. Chemotherapy-related myelosuppression as a marker of survival in epithelial ovarian cancer patients. Gynecologic Oncology. 2008;108:336–41.
- Vasey PA, Jayson GC, Gordon A, Gabra H, Coleman R, Atkinson R, Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst. 2004;96:1682–91.
- Rankin EM, Mill L, Kaye SB, Atkinson R, Cassidy L, Cordiner J, A randomised study comparing standard dose carboplatin with chlorambucil and carboplatin in advanced ovarian cancer. Br J Cancer. 1992;65:275–81.
- Carpenter JT, Maddox WA, Laws HL, Wirtschafter DD, Soong SJ. Favorable factors in the adjuvant therapy of breast cancer. Cancer. 1982;50:18–23.
- Yosef H, Slater A, Keen CW, Bunting JS, Hope-Stone H, Parmar H, Prednimustine (Sterecyt) versus cyclophosphamide both in combination with methotrexate and 5-fluorouracil in the treatment of advanced breast cancer. Eur J Cancer. 1993;29A:1100–5.
- Saarto T, Blomqvist C, Rissanen P, Auvinen A, Elomaa I. Haematological toxicity: a marker of adjuvant chemotherapy efficacy in stage II and III breast cancer. Br J Cancer. 1997;75:301–5.
- Poikonen P, Saarto T, Lundin J, Joensuu H, Blomqvist C. Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF. Br J Cancer. 1999;80:1763–6.
- Mayers C, Panzarella T, Tannock IF. Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma. Cancer. 2001;91:2246–57.
- Cameron DA, Massie C, Kerr G, Leonard RC. Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer. Br J Cancer. 2003;89:1837–42.
- Koutras AK, Fountzilas G, Dafni U, Dimopoulos MA, Pectasides D, Klouvas G, Myelotoxicity as a prognostic factor in patients with advanced breast cancer treated with chemotherapy: a pooled analysis of two randomised trials conducted by the Hellenic Cooperative Oncology Group. Anticancer Res. 2008;28:2913–20.
- Kumpulainen EJ, Hirvikoski PP, Johansson RT. Neutropenia during adjuvant chemotherapy of breast cancer is not a predictor of outcome. Acta Oncologica. 2009.
- Di Maio M, Gridelli C, Gallo C, Shepherd F, Piantedosi FV, Cigolari S, Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials. Lancet Oncol. 2005;6:669–77.
- Banerji U, Ashley S, Coward J, Hughes S, Zee Y, Benepal T, The association of chemotherapy induced neutropenia on treatment outcomes in small cell lung cancer. Lung Cancer. 2006;54:371–7.